662 related articles for article (PubMed ID: 34089060)
1. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
2. Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.
Spindle TR; Cone EJ; Kuntz D; Mitchell JM; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2020 Mar; 44(2):109-125. PubMed ID: 31682266
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
[TBL] [Abstract][Full Text] [Related]
4. Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
Sholler DJ; Zamarripa CA; Spindle TR; Martin EL; Kuntz D; Vandrey R; Grabenauer M
J Anal Toxicol; 2022 Oct; 46(8):882-890. PubMed ID: 35770374
[TBL] [Abstract][Full Text] [Related]
5. Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.
Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
J Anal Toxicol; 2020 Jan; 44(1):1-14. PubMed ID: 31095692
[TBL] [Abstract][Full Text] [Related]
6. Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.
Huestis MA; Sempio C; Newmeyer MN; Andersson M; Barnes AJ; Abulseoud OA; Blount BC; Schroeder J; Smith ML
J Anal Toxicol; 2020 Oct; 44(7):651-660. PubMed ID: 32369162
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products.
Zamarripa CA; Tilton HE; Lin S; Cone EJ; Winecker RE; Flegel RR; Kuntz D; Beals M; Jacques M; Clark M; Welsh ER; Wagner L; Bonn-Miller MO; Vandrey R; Spindle TR
J Anal Toxicol; 2024 Mar; 48(2):81-98. PubMed ID: 38217086
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.
Schlienz NJ; Cone EJ; Herrmann ES; Lembeck NA; Mitchell JM; Bigelow GE; Flegel R; LoDico CP; Hayes ED; Vandrey R
J Anal Toxicol; 2018 May; 42(4):232-247. PubMed ID: 29300962
[TBL] [Abstract][Full Text] [Related]
10. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
13. 11-Nor-9-Carboxy-Δ8-Tetrahydrocannabinol, 7-Carboxy Cannabidiol, and 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol in Urine by LC-MS/MS.
Hughs ML; McMillin GA
Methods Mol Biol; 2024; 2737():161-174. PubMed ID: 38036820
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.
Lin L; Amaratunga P; Reed J; Huang P; Lemberg BL; Lemberg D
J Anal Toxicol; 2022 Feb; 46(1):76-88. PubMed ID: 33270860
[TBL] [Abstract][Full Text] [Related]
15. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
Gustafson RA; Kim I; Stout PR; Klette KL; George MP; Moolchan ET; Levine B; Huestis MA
J Anal Toxicol; 2004 Apr; 28(3):160-7. PubMed ID: 15107145
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.
Swortwood MJ; Newmeyer MN; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
Drug Test Anal; 2017 Jun; 9(6):905-915. PubMed ID: 27647820
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.
Coulter C; Wagner JR
J Anal Toxicol; 2021 Sep; 45(8):807-812. PubMed ID: 34137890
[TBL] [Abstract][Full Text] [Related]
19. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Lee D; Karschner EL; Milman G; Barnes AJ; Goodwin RS; Huestis MA
Drug Alcohol Depend; 2013 Jun; 130(1-3):68-76. PubMed ID: 23146820
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Cannabidiol, ∆9- and ∆8-Tetrahydrocannabinol and Metabolites in Workplace Drug Testing Urine Specimens.
Vikingsson S; Winecker RE; Cone EJ; Kuntz DJ; Dorsey B; Jacques M; Senter M; Flegel RR; Hayes ED
J Anal Toxicol; 2022 Oct; 46(8):866-874. PubMed ID: 35260906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
